Life Science Nation Newsletter  |  November 6, 2014  |  Issue 87

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Accelerator
Life Science Investor Mandates (Oct. 29 - Nov. 5)

Looking Opportunistically in the Life Science Space

Seeking Early Stage Therapeutics and Devices
Seeking Early Stage European Life Science Opportunities
In This Issue

109 Investors from 20 Countries- October Mandate Roundup 

 

The Lure of The Shipping Product, and Why It's A Compelling Opportunity: RESI Commercializing Medtech Innovation Panel Announcement 

 

LSN Research Puts Boots on the Ground in Asia
 

READ MORE

LSN Videos
RESI 2014 Fall, Fenway Park
  
RESI 3 Family Office Panel
  
RESI 3 Outbound Fundraising Panel 
RESI 3 Corporate Venture Capital Panel
The Life Science Executive's Fundraising Manifesto
109 Investors from 20 Countries- October Mandate Roundup 

By Lucy Parkinson, Senior Research Manager, LSN 

 

Last week, the LSN research team closed out the first month of the last quarter, tallying and analyzing the investor mandates gathered throughout October. Our researchers spoke with 109 deal-sourcing executives last month. As usual, these investors were highly diverse, hailing from 20 countries and representing 9 investor categories; 12 of the 109 were investors from family offices and private-wealth funds. (See Figure 1.)...


 

The Lure of The Shipping Product, and Why It's A Compelling Opportunity: RESI Commercializing Medtech Innovation Panel Announcement 

By Tom Crosby, RESI Conference Manager, LSN 

 

At the next RESI Conference in January, LSN will expand its Medtech Track. One of several new panels, Commercializing Medtech Innovation will focus on investors who consider later-stage opportunities, such as devices that are about to reach commercialization or those that have recently been approved and begun shipping. In keeping with the goals of the RESI Conference, this session will be compelling for earlier-stage device entrepreneurs as well, as panelists will discuss the nuances of emerging companies building relationships with investors.

 

Moderated by David Cassak, Managing Partner at Innovation in Medtech, the audience will hear from:

  • Dennis Purcell, Senior Managing Partner, Aisling Capital
  • Garheng Kong, Managing Partner, Healthquest Capital
  • Janice Borque, Managing Director, Hercules Technology Growth Capital
  • Michael Bianco, General Partner, Life Science Equity Partners
  • Mark Chin, Vice President, Longitude Capital

LSN Research Puts Boots on the Ground in Asia 
By Michael Quigley, Director of Research, LSN

 

At the beginning of October, LSN established a presence in the Asia-Pacific region so we could increase the number of mandates from investors who are unreachable during our normal business hours. Since that initiative began, we have interviewed more than 25 deal-sourcing executives interested in the life science space. These investors are based in several countries, including Australia, China, India, Japan, Korea, New Zealand, and Singapore. A significant reason for this success could be that the investors in these countries tend to be much more responsive to cold calling, which is less common in the region, and emailing. However, when analyzing the mandates from these investors, it appears that their desire for quality deal flow from U.S. and European companies is also motivating them to share their investment criteria with us...

 


 www.lifesciencenation.com

Address: 9B Hamilton Place, Boston, MA, 02108, USA

Phone: +1 (617) 600-0668

Email: [email protected]

follow us: Follow us on Twitter View our profile on LinkedIn  

Editors:
Michael Quigley, Director of Research, LSN
Nono Hu, Senior Manager, Branding & Messaging, LSN